Albert Behne will be re-elected. But with the worst result of all board members.
In the board election, shareholders in vaccine maker Lonza gave President Albert Biheny a lesson. Almost twelve percent of the shareholders voted against his re-election. He did not receive any number of votes when he was re-elected Chairman of the Board of Directors. This gave Chairman Lonza the worst election result of all eight re-elected board members.
The remaining seven directors were re-elected with nearly 99% of the vote, and Baehny with less than 88%. His result is also much worse than the result of the previous year.
Lonza has not commented on shareholder gossip. A clear explanation is that Lonza owners have not agreed to single Baehny’s operation in connection with government vaccine production. Behni stated that Switzerland has an opportunity to secure its vaccine capabilities through investment. Baehny later made a partial move back in the SRF. “I’d like to correct it a little bit. I asked him: Is the federal government interested in investing in capabilities? Moderna and Lonza are now expanding their capabilities – without federal government interference.